Leadership & Pay ·
Gyre Therapeutics appoints Ying Luo as CEO and Thomas Eastling as CFO
GYREGyre Therapeutics, Inc.
Gyre Therapeutics, Inc. entered into employment agreements with Ying Luo, Ph.D., to serve as Chief Executive Officer, and Thomas Eastling to serve as Chief Financial Officer. Dr. Luo’s agreement includes a $500,000 annual base salary and a target bonus of $150,000 for 2026. Mr. Eastling’s agreement provides a $339,066 annual base salary and a target bonus of $70,000 for 2026. Both agreements are at-will and include standard severance provisions, including COBRA reimbursement and accelerated equity vesting upon termination without cause or for good reason, as well as enhanced change-of-control protections. Gyre Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.